Comparison of Mortality Prediction Between the Model for End-Stage Liver Disease-3.0 (MELD-3.0) and the Model for End-Stage Liver Disease-Lactate (MELD-La) in Korean Patients with Liver Cirrhosis

<i>Background and Objectives</i>: The Model for End-Stage Liver Disease (MELD) score has widely been used for mortality prediction in liver cirrhosis (LC) patients and transplantation allocation. There have been recent modifications of MELD scores, such as MELD-Lactate (MELD-La) and MELD...

Full description

Saved in:
Bibliographic Details
Main Authors: Seung-Kang Yoo, Jeong-Han Kim, Won-Hyeok Choe, So-Young Kwon
Format: Article
Language:English
Published: MDPI AG 2025-03-01
Series:Medicina
Subjects:
Online Access:https://www.mdpi.com/1648-9144/61/3/494
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850279724431966208
author Seung-Kang Yoo
Jeong-Han Kim
Won-Hyeok Choe
So-Young Kwon
author_facet Seung-Kang Yoo
Jeong-Han Kim
Won-Hyeok Choe
So-Young Kwon
author_sort Seung-Kang Yoo
collection DOAJ
description <i>Background and Objectives</i>: The Model for End-Stage Liver Disease (MELD) score has widely been used for mortality prediction in liver cirrhosis (LC) patients and transplantation allocation. There have been recent modifications of MELD scores, such as MELD-Lactate (MELD-La) and MELD-3.0. The goal of this study was to compare MELD, MELD-La, and MELD-3.0 in predicting mortality among LC patients in Korea. <i>Materials and Methods</i>: This is a retrospective, single-centered study in which LC patients admitted to Konkuk University Hospital between January 2011 and December 2022 were enrolled and reviewed. Predictive values for 1- and 3-month mortality for MELD, MELD-La, and MELD-3.0 were calculated using the area under the receiver operating characteristic (AUROC) curve. Differences between AUROCs were statistically analyzed using DeLong’s test. <i>Results</i>: A total of 1152 patients were initially included in this study. Among them, 165 (14.3%) patients died within one month, and 211 (19.7%) died within three months. The AUROCs for 1-month mortality of MELD, MELD-La, and MELD-3.0 were 0.808, 0.79, and 0.807, respectively. For the 3-month mortality of MELD, MELD-La, and MELD-3.0, the AUROCs were 0.805, 0.753, and 0.817, respectively. Multiple comparisons of ROC curves demonstrated that MELD and MELD-3.0 reflected the 3-month mortality prediction of LC patients better than MELD-La (<i>p</i> = 0.0018, <i>p</i> = 0.0003, respectively). <i>Conclusions</i>: This study demonstrated that MELD and MELD-3.0 outperformed MELD-La in predicting the 3-month mortality for LC patients. However, there was no significant difference between MELD and MELD-3.0 in predicting LC patient mortality.
format Article
id doaj-art-c63151cb230b4c008df36860255b5ed9
institution OA Journals
issn 1010-660X
1648-9144
language English
publishDate 2025-03-01
publisher MDPI AG
record_format Article
series Medicina
spelling doaj-art-c63151cb230b4c008df36860255b5ed92025-08-20T01:49:00ZengMDPI AGMedicina1010-660X1648-91442025-03-0161349410.3390/medicina61030494Comparison of Mortality Prediction Between the Model for End-Stage Liver Disease-3.0 (MELD-3.0) and the Model for End-Stage Liver Disease-Lactate (MELD-La) in Korean Patients with Liver CirrhosisSeung-Kang Yoo0Jeong-Han Kim1Won-Hyeok Choe2So-Young Kwon3Department of Internal Medicine, Konkuk University Medical Center, Seoul 05030, Republic of KoreaDepartment of Internal Medicine, Konkuk University Medical Center, Seoul 05030, Republic of KoreaDepartment of Internal Medicine, Konkuk University Medical Center, Seoul 05030, Republic of KoreaDepartment of Internal Medicine, Konkuk University Medical Center, Seoul 05030, Republic of Korea<i>Background and Objectives</i>: The Model for End-Stage Liver Disease (MELD) score has widely been used for mortality prediction in liver cirrhosis (LC) patients and transplantation allocation. There have been recent modifications of MELD scores, such as MELD-Lactate (MELD-La) and MELD-3.0. The goal of this study was to compare MELD, MELD-La, and MELD-3.0 in predicting mortality among LC patients in Korea. <i>Materials and Methods</i>: This is a retrospective, single-centered study in which LC patients admitted to Konkuk University Hospital between January 2011 and December 2022 were enrolled and reviewed. Predictive values for 1- and 3-month mortality for MELD, MELD-La, and MELD-3.0 were calculated using the area under the receiver operating characteristic (AUROC) curve. Differences between AUROCs were statistically analyzed using DeLong’s test. <i>Results</i>: A total of 1152 patients were initially included in this study. Among them, 165 (14.3%) patients died within one month, and 211 (19.7%) died within three months. The AUROCs for 1-month mortality of MELD, MELD-La, and MELD-3.0 were 0.808, 0.79, and 0.807, respectively. For the 3-month mortality of MELD, MELD-La, and MELD-3.0, the AUROCs were 0.805, 0.753, and 0.817, respectively. Multiple comparisons of ROC curves demonstrated that MELD and MELD-3.0 reflected the 3-month mortality prediction of LC patients better than MELD-La (<i>p</i> = 0.0018, <i>p</i> = 0.0003, respectively). <i>Conclusions</i>: This study demonstrated that MELD and MELD-3.0 outperformed MELD-La in predicting the 3-month mortality for LC patients. However, there was no significant difference between MELD and MELD-3.0 in predicting LC patient mortality.https://www.mdpi.com/1648-9144/61/3/494MELDMELD-lactateMELD-3.0mortality predictionliver cirrhosis
spellingShingle Seung-Kang Yoo
Jeong-Han Kim
Won-Hyeok Choe
So-Young Kwon
Comparison of Mortality Prediction Between the Model for End-Stage Liver Disease-3.0 (MELD-3.0) and the Model for End-Stage Liver Disease-Lactate (MELD-La) in Korean Patients with Liver Cirrhosis
Medicina
MELD
MELD-lactate
MELD-3.0
mortality prediction
liver cirrhosis
title Comparison of Mortality Prediction Between the Model for End-Stage Liver Disease-3.0 (MELD-3.0) and the Model for End-Stage Liver Disease-Lactate (MELD-La) in Korean Patients with Liver Cirrhosis
title_full Comparison of Mortality Prediction Between the Model for End-Stage Liver Disease-3.0 (MELD-3.0) and the Model for End-Stage Liver Disease-Lactate (MELD-La) in Korean Patients with Liver Cirrhosis
title_fullStr Comparison of Mortality Prediction Between the Model for End-Stage Liver Disease-3.0 (MELD-3.0) and the Model for End-Stage Liver Disease-Lactate (MELD-La) in Korean Patients with Liver Cirrhosis
title_full_unstemmed Comparison of Mortality Prediction Between the Model for End-Stage Liver Disease-3.0 (MELD-3.0) and the Model for End-Stage Liver Disease-Lactate (MELD-La) in Korean Patients with Liver Cirrhosis
title_short Comparison of Mortality Prediction Between the Model for End-Stage Liver Disease-3.0 (MELD-3.0) and the Model for End-Stage Liver Disease-Lactate (MELD-La) in Korean Patients with Liver Cirrhosis
title_sort comparison of mortality prediction between the model for end stage liver disease 3 0 meld 3 0 and the model for end stage liver disease lactate meld la in korean patients with liver cirrhosis
topic MELD
MELD-lactate
MELD-3.0
mortality prediction
liver cirrhosis
url https://www.mdpi.com/1648-9144/61/3/494
work_keys_str_mv AT seungkangyoo comparisonofmortalitypredictionbetweenthemodelforendstageliverdisease30meld30andthemodelforendstageliverdiseaselactatemeldlainkoreanpatientswithlivercirrhosis
AT jeonghankim comparisonofmortalitypredictionbetweenthemodelforendstageliverdisease30meld30andthemodelforendstageliverdiseaselactatemeldlainkoreanpatientswithlivercirrhosis
AT wonhyeokchoe comparisonofmortalitypredictionbetweenthemodelforendstageliverdisease30meld30andthemodelforendstageliverdiseaselactatemeldlainkoreanpatientswithlivercirrhosis
AT soyoungkwon comparisonofmortalitypredictionbetweenthemodelforendstageliverdisease30meld30andthemodelforendstageliverdiseaselactatemeldlainkoreanpatientswithlivercirrhosis